Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of YHP1807 and YHR1901 (Rivaroxaban) in Healthy Volunteers
NCT05418803Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolism (2 arms), sponsored by Yuhan. Primary endpoints: Area Under the Plasma Concentration-Time Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started Jan 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT05418803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418803.